I believe the sentiment around Moderna began to go from bearish to a mixed condition in June, after the company received FDA approval for their next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283).

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. also in the 2025-2026 respiratory virus season, alongside Spikevax.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug substance plant in Japan. | The company attributed its decision to ...

Moderna said on Friday it will not proceed with plans to build a messenger RNA manufacturing plant in Japan due to "changes in the business environment" around the world and in Japan.

But, if its pipeline of new products comes into play, including work on new treatments in oncology, then Moderna stock -- down 74% in the year ending July 21 -- might have some great long-term ...

CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

Moderna has struggled since COVID-19 vaccine demand has shrunk. The stock has correspondingly declined, as revenue has nosedived over the last few years. The long game is clinical trials in ...

Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted an opinion recommending marketing authorization for an updated ...

Within two years, 95% of all cognitive tasks performed by humans will be better executed by AI. This prediction, shared by AI experts from DeepMind, Meta and MIT at the MIT AI Day at Davos in ...

Algorithms running on quantum computers could have big implications for drug discovery, IBM says.